UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1145-12
Program Prior Authorization/Notification
Medication Zydelig® (idelalisib)
P&T Approval Date 10/2014, 10/2015, 9/2016, 9/2017, 9/2018, 9/2019, 9/2020, 10/2021,
5/2022, 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Zydelig (idelalisib) is a kinase inhibitor indicated for the treatment of patients with relapsed
chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom
rituximab alone would be considered appropriate therapy due to other co-morbidities.1,2 The
National Cancer Comprehensive Network (NCCN) also recommends the use of Zydelig as
second-line and subsequent therapy as a single agent or in combination with rituximab for
CLL/SLL with del(17p)/TP53 mutation in patients who have indications for treatment.2
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Zydelig will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
1. Initial Authorization
a. Zydelig will be approved based on both of the following criteria:
(1) Diagnosis of Chronic Lymphocytic Leukemia (CLL) / small lymphocytic
lymphoma (SLL)
-AND-
(2) One of the following:
© 2025 UnitedHealthcare Services, Inc.
1
(a) Disease has relapsed
(b) Disease is refractory
Authorization will be issued for 12 months.
2. Reauthorization
a. Zydelig will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Zydelig therapy
Authorization will be issued for 12 months.
C. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Zydelig [package insert]. Foster City, CA: Gilead Science, Inc. February 2022.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
http://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed
March 27, 2025.
Program Prior Authorization/Notification - Zydelig (idelalisib)
Change Control
10/2014 New program for Zydelig approved by FDA on 6/23/2014.
10/2015 Annual review. Added coverage for gastric and nongastric MALT
lymphomas, and splenic marginal zone lymphoma. Revised CLL/SLL
and primary cutaneous B-cell lymphoma criteria. Updated background
and references.
9/2016 Annual review. Added coverage for additional cutaneous B-cell
lymphoma diseases. Updated references.
© 2025 UnitedHealthcare Services, Inc.
2
9/2017 Annual review. Added coverage for additional nodal marginal zone
lymphoma. Updated background and references.
9/2018 Annual review. No changes to the coverage criteria. Updated
references.
9/2019 Annual review. Updated NHL section based on NCCN guidelines.
Updated references. Added general NCCN recommended review
criteria.
9/2020 Annual review. No changes to coverage criteria. Updated background
references.
10/2021 Annual review. Reclassified Non-Hodgkin Lymphoma to B-cell
Lymphomas to align with NCCN guidelines. Updated references.
5/2022 Annual review. Removed coverage for follicular B-cell non-Hodgkin
lymphoma, small lymphocytic lymphoma, gastric and nongastric
MALT lymphomas, splenic marginal zone lymphoma, and nodal
marginal zone lymphoma based on package insert and NCCN
guidelines. Updated background and references.
5/2023 Annual review. Added state mandate. Updated background and clarified
criteria for CLL/SLL per NCCN guidelines. Updated references.
5/2024 Annual review. Updated references.
5/2025 Annual review. No changes to clinical criteria. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3